1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023


GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

SkyePharma’s Flutiform is an FDC of fluticasone propionate and formoterol fumarate. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budesonide and two times more potent than the active metabolite of beclomethasone dipropionate. Formoterol fumarate is a LABA that exerts its bronchodilatory activity locally in the lung. LABAs act by stimulating intracellular adenylate cyclase, resulting in increased cAMP levels, which, in turn, cause relaxation of bronchial smooth muscle, inhibiting the release of hypersensitivity mediators, such as histamine and leukotrienes, from cells, especially mast cells.


- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Flutiform including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Flutiform for the top seven countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Flutiform performance
- Obtain sales forecast for Flutiform from 2013-2023 in top seven countries (France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Flutiform (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 20
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 27
6 Flutiform (fluticasone propionate/formoterol fumarate) 31
6.1 Overview 31
6.2 Efficacy 32
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 34
7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed Asthma Patients 43
7.4.2 Percent Drug-Treated Patients 44
7.4.3 General Pricing Assumptions 44
7.4.4 Individual Drug Assumptions 45
7.4.5 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 46
7.6 About the Authors 49
7.6.1 Author 49
7.6.2 Author/Reviewer 49
7.6.3 Reviewer 50
7.6.4 Global Head of Healthcare 51
7.7 About GlobalData 52
7.8 Disclaimer 52

1.1 List of Tables

Table 1: Symptoms of Asthma 16
Table 2: Treatment Guidelines for Asthma by Country 18
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 19
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 22
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 24
Table 6: Leading Treatments for Asthma, 2014 30
Table 7: Product Profile - Flutiform 32
Table 8: Efficacy - Flutiform Versus Advair 33
Table 9: Safety - Flutiform Versus Advair 33
Table 10: Flutiform SWOT Analysis, 2014 34
Table 11: Global Sales Forecast ($) for Flutiform, 2013-2023 35
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 48

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 21
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.